Drugs / K27M peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02960230 | Nov 2016 → Dec 2023 | diffuse midline glioma, H3 K27M-mutant | Sabine Mueller, MD, PhD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K27M peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02960230 ↗ |
| Modality | Vaccine | “specific peptide vaccine” NCT02960230 ↗ |